Back to "A higher weight loss was significantly a..."
Strong Support
correlational
Analysis v1
History

In adults with overweight or obesity who are taking incretin-based therapies, those who lose more weight tend to have larger decreases in both their systolic and diastolic blood pressure.

47
Pro
0
Against

Evidence from Studies

Supporting (1)

47

Community contributions welcome

47

Effect of Incretin-Based Therapies on Blood Pressure: A Systematic Review and Meta-Analysis.

Systematic Review With Meta-Analysis
Human
2026 May 15

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Sign up to see full verdict

Source Study

Effect of Incretin-Based Therapies on Blood Pressure: A Systematic Review and Meta-Analysis.

Score: 47
DOI: 10.1093/eurjpc/zwaf560

Similar Assertions

Medications called incretin-based therapies, such as GLP-1 receptor agonists, lower systolic blood pressure by about 3.4 mmHg and diastolic blood pressure by about 0.9 mmHg in adults who have overweight or obesity.

47
0
74%

When obese adults take medicines to lose weight, their blood pressure tends to go down a little bit compared to those who take a sugar pill, which might help lower their risk of heart problems.

48
0
74%

Medications called incretin-based therapies, used for type 2 diabetes, are associated with better heart health due to their effects on reducing inflammation, lowering blood pressure, and helping with weight loss.

47
0
71%